

REMARKS

Amendments

On March 27, 2002, applicants submitted a Second Preliminary Amendment which added claims 35-59. However, claims 47-50 contained a typographical error (the β symbol was omitted in from the claims). Also, in claim 57 "combination" was misspelled. These typographical errors are corrected by the present amendments. New claims 60-63 are directed to the elected species.

Election

In response to the election of species requirement set forth in the Office Action of March 26, 2003, applicants' hereby elect the combination of (-)- β -L-Dioxolane-Cytidine (β -L-oddC) and Doxorubicin. Applicants understand that examination will not continue pursuant to MPEP §809.02 (c).

Favorable consideration of the instant application is respectfully requested.

Respectfully submitted,



Brian R. Heaney (Reg. No. 32,542)
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P. C.
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 812-5308
Internet address: heaney@mwzb.com

Filed: April 17, 2003

VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE CLAIMS:

Please amend claims 47-50 and 57 as follows:


--47. A composition according to claim 36, wherein said compound is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.

48. A composition according to claim 36, wherein said compound is (-)- β -Dioxolane-5-fluoro-Cytidine (5-FddC) or a pharmaceutically acceptable salt thereof.

49. A composition according to claim 47, wherein said compound is (-)- β -L-Dioxolane-Cytidine (β -L-oddC).

50. A composition according to claim 48, wherein said compound is (-)- β -Dioxolane-5-fluoro-Cytidine (5-FddC).

57. A pharmaceutical combination ~~combination~~ comprising at least one compound of formula I




(I)

wherein

B is cytosine or 5-fluorocytosine,

R is H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, or



Rc is in each case independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or a hydroxy protecting group, and wherein said compound is substantially in the form of the (-) enantiomer; and

a chemotherapeutic agent selected from Asparaginase, Bleomycin, Busulfan, Carmustine, Chlorambucil, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin, Doxorubicin, Etoposide, Fludarabine, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Lomustine, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Pentostatin, Procarbazine, 6-Thioguanine, Topotecan, Vinblastine, Vincristine, Dexamethasone, Retinoic acid and Prednisone.--